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Abstract
Background: Differences in sweet taste perception among species depend on structural variations of the
sweet taste receptor. The commercially used isovanillyl sweetener neohesperidin dihydrochalcone
activates the human but not the rat sweet receptor TAS1R2+TAS1R3. Analysis of interspecies
combinations and chimeras of rat and human TAS1R2+TAS1R3 suggested that the heptahelical domain of
human TAS1R3 is crucial for the activation of the sweet receptor by neohesperidin dihydrochalcone.
Results: By mutational analysis combined with functional studies and molecular modeling we identified a
set of different amino acid residues within the heptahelical domain of human TAS1R3 that forms the
neohesperidin dihydrochalcone binding pocket. Sixteen amino acid residues in the transmembrane
domains 2 to 7 and one in the extracellular loop 2 of hTAS1R3 influenced the receptor's response to
neohesperidin dihydrochalcone. Some of these seventeen residues are also part of the binding sites for the
sweetener cyclamate or the sweet taste inhibitor lactisole. In line with this observation, lactisole inhibited
activation of the sweet receptor by neohesperidin dihydrochalcone and cyclamate competitively, whereas
receptor activation by aspartame, a sweetener known to bind to the N-terminal domain of TAS1R2, was
allosterically inhibited. Seven of the amino acid positions crucial for activation of hTAS1R2+hTAS1R3 by
neohesperidin dihydrochalcone are thought to play a role in the binding of allosteric modulators of other
class C GPCRs, further supporting our model of the neohesperidin dihydrochalcone pharmacophore.
Conclusion: From our data we conclude that we identified the neohesperidin dihydrochalcone binding
site at the human sweet taste receptor, which overlaps with those for the sweetener cyclamate and the
sweet taste inhibitor lactisole. This readily delivers a molecular explanation of our finding that lactisole is
a competitive inhibitor of the receptor activation by neohesperidin dihydrochalcone and cyclamate. Some
of the amino acid positions crucial for activation of hTAS1R2+hTAS1R3 by neohesperidin dihydrochalcone
are involved in the binding of allosteric modulators in other class C GPCRs, suggesting a general role of
these amino acid positions in allosterism and pointing to a common architecture of the heptahelical
domains of class C GPCRs.
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Genetic, anatomical and functional studies provide com-
pelling evidence that the vast majority of sweet taste per-
ception is mediated by G-protein coupled receptors
(GPCR) of the TAS1R-gene family, which comprises the
members TAS1R1-3 [1-6]. TAS1Rs belong to the class C
GPCRs and are distantly related to the calcium sensing
receptor, metabotropic glutamate receptors, V2R pherom-
one receptors, and GABAB receptors [3]. In situ hybridiza-
tion studies revealed that TAS1R3 is coexpressed with
TAS1R1 or TAS1R2 in taste receptor cells [5,6]. This obser-
vation suggests that the functional receptor, like other
class C GPCRs [7], may be a heteromer of two subunits.
Indeed, functional assays revealed that the combination
of TAS1R1+TAS1R3 is activated by umami tasting com-
pounds, while TAS1R2+TAS1R3 responds to sweeteners
[4,5,8].
The human sweet taste receptor is sensitive to the sweet
proteins thaumatin, brazzein and monellin, the artificial
sweeteners aspartame and cyclamate as well as to the
sweet inhibitor lactisole whereas its rodent homolog is
not [4]. This is in line with corresponding variations in
sweet perception across species [9-11]. Studies with chi-
meric receptors revealed that replacement of the large N-
terminal extracellular domain of rat Tas1r2 by its human
counterpart created a receptor that responded to aspar-
tame and neotame when coexpressed with hTAS1R3.
Additional mutations in the N-terminal domain of
human TAS1R2 impaired the activation of the sweet taste
receptor by aspartame, thus suggesting that the N-termi-
nal part of TAS1R2 is involved in the binding of these
sweeteners [12,13]. Similar studies showed that amino
acids in the cysteine-rich region of human TAS1R3 that
connects the N-terminal extracellular domain to the seg-
ment containing the heptahelical domain determines the
response to sweet proteins such as brazzein and monellin
[12]. Conversely, replacement of the heptahelical domain
of rat Tas1r3 by the corresponding part of the human
receptor led to a chimera that responded to lactisole and
cyclamate when coexpressed with rat Tas1r2 [13]. This
suggests that the binding sites for cyclamate and lactisole
are located in the heptahelical domain of hTAS1R3.
Indeed, mutational analysis in combination with molecu-
lar modeling studies of the heptahelical domain of
TAS1R3 revealed that the sweet inhibitor lactisole and the
sweetener cyclamate have overlapping binding sites in the
heptahelical domain of the human TAS1R3 subunit
[14,15]. Recently, analysis of rat-human sweet taste recep-
tor chimeras revealed that the heptahelical domain of
hTAS1R3 is also crucial for the activation by the sweetener
neohesperidin dihydrochalcone (NHDC) [16]. NHDC is
added to various foods and beverages as a low caloric
sweetener [17], but its use is limited by some unwanted
sensory properties such as a delayed onset and a long lin-
gering menthol-licorice like sweetness [18,19]. Thus, a
detailed molecular understanding of the interactions of
the sweet receptor with NHDC may contribute to the
rational design of analogues with improved sensory prop-
erties. We therefore investigated the binding pocket of
neohesperidin dihydrochalcone at the human sweet taste
receptor.
Results
Analysis of receptor chimeras reveals that NHDC requires 
the human TAS1R3 heptahelical domain
The isovanillyl compound NHDC (Fig. 1A) activates the
human but not the rodent sweet taste receptor (Fig. 1B).
In order to elucidate the putative binding site for NHDC,
we cotransfected mixtures of plasmid DNAs for the rat
and human TAS1R2 and TAS1R3 receptor subunits in
HEK293T cells stably expressing the chimeric G-protein
G16Gust44 and measured cellular calcium responses by
fluorometry following bath application of various sweet
tasting compounds. We found that NHDC elicited cal-
cium responses in cells transfected with human TAS1R3
and rat Tas1r2 cDNA, whereas it did not in cells trans-
fected with the opposite combination (Fig. 1C). By replac-
ing the heptahelical domain of rat Tas1r3 with that of
human TAS1R3 we produced a chimeric receptor that was
sensitive for NHDC when coexpressed with rat Tas1r2
(Fig. 1C). In marked contrast, all receptors that contain
the entire rat Tas1r3 or its heptahelical domain did not
respond to NHDC (Fig. 1C). Notably, although the ampli-
tudes and the response pattern of the receptor chimaeras
varied (for details see Ref. 13, supplement) we can dem-
onstrate that all tested receptor chimeras were functional
because they could be activated by at least one sweetener
(Fig. 1C, D). These results clearly indicate that the hepta-
helical domain of TAS1R3 appears to be crucially involved
in the activation of the sweet receptor by NHDC.
Receptor activation by NHDC is competitively inhibited by 
lactisole
Recently, it has been shown that the binding sites for the
sweetener cyclamate and the sweet inhibitor lactisole
overlap in the heptahelical domain of TAS1R3 [14,15].
We therefore reasoned that the NHDC binding site might
also overlap with that for lactisole. In this case one would
expect that lactisole competitively inhibits the activation
of hTAS1R2/hTAS1R3 by NHDC and cyclamate. In con-
trast, receptor activation by sweeteners that bind to other
sites should be allosterically inhibited. To verify this
assumption we recorded concentration-response curves
for NHDC, cyclamate, acesulfame K and aspartame in the
presence of different concentrations of lactisole in cells
expressing hTAS1R2/hTAS1R3 (Fig. 2).
In line with these expectations lactisole did not alter the
EC50 values for acesulfame K but reduced the signal ampli-Page 2 of 12
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teric inhibitor of acesulfame K. Likewise, lactisole
diminished the signal amplitudes induced by aspartame
(Fig. 2B), which is consistent with an allosteric inhibition
of aspartame-mediated receptor activation. Interestingly,
in case of aspartame, the pronounced reductions in signal
amplitudes were accompanied by a right-shift in the EC50
values (Fig. 2B, E). This may be due to an influence of lac-
tisole on the aspartame binding site by negative coopera-
tivity [20]. In contrast, lactisole did not diminish the
signal amplitudes elicited by NHDC or cyclamate (Fig.
2C, D). Instead, lactisole clearly increased the EC50 values
of these compounds ~fourfold (Fig. 2E). This observed
competitive inhibition suggests that the binding sites for
lactisole, cyclamate and NHDC overlap in the heptaheli-
cal domain of human TAS1R3. Interestingly, we observed
Chemical structure and calcium responses elicited by neo-hesperidin dihydrochalconeFigure 1
Chemical structure and calcium responses elicited by 
neohesperidin dihydrochalcone. (A) Structure of neo-
hesperidin dihydrochalcone. Numbers denote carbon atom 
positions. (B) Representative calcium traces elicited upon 
stimulation with different concentrations of neohesperidin 
dihydrochalcone (NHDC) in HEK293T-G16Gust44 cells 
cotransfected with DNA for hTAS1R2/hTAS1R3. (C,D) Cal-
cium responses of cells cotransfected with DNA for different 
rat and human TAS1R subunits or chimeras upon stimulation 
with 1 mM NHDC (C), or 30 mM D-Tryptophan (D). R, rat 
receptor subunit; H human receptor subunit; HR, receptor 
chimera comprising the N-terminal extra cellular domain of 
the human receptor subunit fused to the corresponding hep-
tahelical domain of the rat; RH, comprising the N-terminal 
extracellular domain of the rat receptor subunit fused to the 
corresponding heptahelical domain of the human receptor.
Inhibition of hTAS1R2/hTAS1R3 by lactisoleFigure 2
Inhibition of hTAS1R2/hTAS1R3 by lactisole. (A-D) 
Concentration responses of cells transfected with hTAS1R2-
hTAS1R3 DNAs to sweetners mixed with different lactisole 
concentrations. No lactisole present (filled circles, solid line), 
50 µM lactisole (filled triangles up, dashed line), and 100 µM 
lactisole (filled squares, dash-dotted line). (E) EC50 values for 
acesulfame K, aspartame, NHDC, and cyclamate in the 
absence or presence of 50 µM and 100 µM lactisole.Page 3 of 12
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While Aspartame and Acesulfam K had constant Hill
slope of ~2 the Hill coefficient for NHDC in the presence
of 0.0 µM, 50 µM or 100 µM lactisole was 0.8, 1.2 and 1.5,
respectively. The calculated Hill coefficient for cyclamate
was 1.6, 2.5 and 2.7, respectively. This may be best
explained by allosteric effects and may therefore indicate
the existence of additional interaction sites either for lac-
tisole or for the sweeteners [21].
NHDC interacts with residues of the lactisole and 
cyclamate binding site
Next, we investigated which amino acids of the binding
sites for lactisole or cyclamate are critical determinants for
receptor activation by NHDC. Therefore, we analyzed the
effect of 16 point mutations (Q636A3.28, R723A5.36,
S729A5.42, A733V5.46, L798I7.36, V779A6.52, R790Qex3,
H734A5.47, Q637E3.29, H641A3.33, S640A3.32, H721Aex2,
F730L5.43, W775A6.48, F778A6.51, L782A6.55) in the hepta-
helical domain of hTAS1R3 that have previously been
shown to influence receptor sensitivity to cyclamate or
lactisole [14,15] on the sweet receptor's response to
NHDC. The effects were measured by recording calcium
responses in HEK293T-G16Gust44 cells coexpressing
hTAS1R2 and the various hTAS1R3 mutants. Cells
expressing the mutant H734A5.47 did not respond to
NHDC, cyclamate, aspartame or acesulfame K (Addi-
tional file 1). We assumed that this mutation generally
impairs the function of the receptor and excluded it from
further analyses. Seven receptor mutants (Q636A3.28,
R723A5.36, S729A5.42, A733V5.46, V779A6.52, R790Qex3,
L798I7.36) showed EC50 values for NHDC similar to that
of the wild type receptor (Table 1, normal script, Addi-
tional file 2), suggesting that these residues have no
impact on the action of NHDC on the sweet receptor. The
eight remaining TAS1R3 mutants, Q637E3.29, S640A3.32,
H641A3.33, H721Aex2, F730L5.43, W775A6.48, F778A6.51,
and L782A6.55 showed at least eightfold higher EC50 values
for NHDC than the wild type receptor (Table 1, bold
script, Additional file 2). The decreased sensitivities of
these eight mutant receptors were specific for NHDC since
their EC50 values for aspartame were not altered (Table 1).
Additionally, immunocytochemical analysis revealed
similar expression patterns for all examined TAS1R3
receptor variants (Additional file 3). Thus, the increased
EC50 values suggest that Q6373.29, H6413.33, S6403.32,
H721ex2, F7305.43, W7756.48, F7786.51, L7826.55 are impor-
tant for the activation of the sweet taste receptor by
NHDC.
Modeling of the NHDC binding site predicts interactions 
with additional residues in the heptahelical domain of 
TAS1R3
To further elucidate the binding mode for NHDC, an
alignment of the seven transmembrane helices of the
hTAS1R3 with the transmembrane helices of bovine rho-
dopsin was performed (Additional file 4). Amino acids
were extracted at helix positions critical for binding of ret-
inal and then combined in a one dimensional amino acid
vector, called ligand pocket vector (LPV) [22]. Amino
acids in the TAS1R3 LPV were considered as likely candi-
dates to affect binding of NHDC. Classical homology
models imply to have the quality of an X-ray crystal struc-
ture and therefore overstress specific, in detail unknown,
Table 1: Effects of various mutations on the activation of the sweet taste receptor by neohesperidin dihydrochalcone (NHDC) and 
aspartame (ASP)
variant NHDC EC50 (mM) NHDC maximal signal 
(% of wt)
ASP EC50 (mM) ASP maximal signal 
(% of wt)
wt 0.1 ± 0.06 100 1.3 ± 0.1 100
Q636A3.28 0.3 ± 0.2 61 ± 29 1.1 ± 0.1 70 ± 18
Q637E3.29 1.5 ± 0.4 51 ± 13 1.7 ± 0.2 51 ± 10
S640A3.32 0.8 ± 0.2 63 ± 18 1.4 ± 0.5 61 ± 40
H641A3.33 1.2 ± 0.4 57 ± 22 1.8 ± 0.4 79 ± 70
H721Aex2 0.8 ± 0.3 66 ± 10 1.6 ± 0.3 60 ± 40
R723A5.36 0.2 ± 0.1 69 ± 71 1.5 ± 0.5 68 ± 50
S729A5.42 0.2 ± 0.1 80 ± 16 0.9 ± 0.4 72 ± 20
F730L5.43 0.9 ± 0.1 70 ± 18 1.7 ± 0.4 87 ± 27
A733V5.46 0.1 ± 0.02 133 ± 8 1.1 ± 0.3 92 ± 80
H734A5.47 n.f. -- n.f. --
W775A6.48 >3 30 ± 41 1.9 ± 0.2 20 ± 30
F778A6.51 1.5 ± 0.4 50 ± 18 1.2 ± 0.1 80 ± 80
V779A6.52 0.2 ± 0.1 88 ± 14 1.2 ± 0.3 52 ± 10
L782A6.55 >3 50 ± 11 1.7 ± 0.3 95 ± 90
R790Qex3 0.1 ± 0.06 77 ± 15 0.9 ± 0.4 71 ± 30
L798I7.36 0.2 ± 0.2 66 ± 26 0.9 ± 0.4 81 ± 5
Receptor variants that affect the NHDC response are shown in bold. Values are given as average over at least three independent experiments ± 
SD. n.f., no response to any tested sweetener. (>), EC50 not calculable because saturation is not reached (Additional file 2).Page 4 of 12
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substantial progress in building homology models and
independently of the level of sophistication of the tech-
niques used, there always remains the risk of a mismatch
between optimized rotamers and ligand binding require-
ments, leading to the rejection of ligands in docking
experiments. We therefore designed a simple TM binding
pocket pharmacophore (Fig. 3A) to avoid atomic details
tending to mask this inherent uncertainty and to concen-
trate on the general topology of the binding site and the
approximate relative orientation of charged, donor/accep-
tor and neutral side chains. Only amino acid residues are
shown which were identified as important for the action
of NHDC by site-directed mutagenesis. NHDC was man-
ually docked into the pharmacophore. For the docking
process in addition to our results also data from structure-
activity relationships of ring substituted dihydrochalcone
sweeteners reported by Whitelaw et al. [23,24] were taken
into account. These studies reported that the hydroxyl
group in the B ring system at C3 of 3'-carboxyhesperitin
dihydrochalcone is essential for its sweet taste. Moreover,
the introduction of a carboxylic acid at the C3' position in
the A ring system enhances the sweetness of the dihydro-
chalcone structure. Projecting this knowledge onto the
chemical structure of NHDC suggests that the OH group
in the C3 position is important for receptor-ligand inter-
actions and the C3' position should be in close proximity
to H6413.33 (Fig. 3A). Furthermore, H6413.33 was already
proposed to interact with the carboxylic acid of lactisole
[15] and the mutational studies of the present report indi-
cate that the binding pockets of these two compounds do
indeed overlap. The proposed binding mode of NHDC
also suggests an interaction of the hydroxyl group at C3
with S6403.32 and the hydroxyl groups at C6' and C2' of
NHDC could potentially interact with polar amino acids
located in TM3 and TM7, such as H6413.33, Q6373.29, and
C8017.39 respectively (Fig. 3A). In addition, favorable
hydrophobic interactions between the B phenyl ring of
NHDC could be envisioned with V6212.58 and F6242.61,
and between the linker of the A and B phenyl ring with
L8007.38 and G8047.42. Furthermore, the model (Fig. 3A)
predicts additional putative interaction sites, such as an
interaction between the C3-hydroxylgroup of NHDC with
S6202.57 in TM2. Moreover, the polar sugar moieties of
NHDC could be interacting with polar amino acids of
TM4 and TM5, e.g. Y6994.60, T7245.37, R7255.38 and
S7265.39.
Validation of the model by functional analysis of 
additional mutants
To verify the predictions of the model we selected 10 addi-
tional amino acids in hTAS1R3 (S6202.57, V6212.58,
F6242.61, Y6994.60, T7245.37, R7255.38, S7265.39, L8007.38,
C8017.39, and G8047.42) as candidates that might also
influence the activation of the sweet receptor by NHDC.
To test their impact on the receptor function we created
fourteen hTAS1R3 variants (S620A2.57, V621L2.58,
V621I2.58, F624L2.61, Y699L4.60, Y699F4.60, T724L5.37,
R725M5.38, S726A5.39, L800F7.38, C801I7.39, C801L7.39,
G804A7.42, and G804V7.42) and tested their responses to
NHDC by calcium imaging after coexpression with
hTAS1R2 in HEK293T-G16Gust44 cells. The results show
Three dimensional on top view of the TAS1R3 heptahelical domain binding pocket mod lFigure 3
Three dimensional on top view of the TAS1R3 hepta-
helical domain binding pocket model. The binding 
pocket is docked with NHDC (A), lactisole (B), and cycla-
mate (C). Intra- and extra cellular loops are removed and the 
helices are directly connected. The transmembrane segments 
(TM1–TM7) are denoted in orange. Important residues are 
labeled in Ballesteros-Weinstein nomenclature in addition to 
the one letter amino acid code. Amino acids that influence 
the activation of the sweet receptor by NHDC are shown as 
spheres. The size of the spheres corresponds to the size of 
the side chain. The spheres are colored according to their 
pharmacophoric properties. Hydrophobic amino acids (F, P, 
M, A, L, I, G, V, W) cyan, H-donor/acceptor (Y, T, S, H, C, N, 
Q) magenta, H-bond donors with a positive charge (R) blue. 
Possible H-bond interactions are presented as dotted lines 
The color of the dotted lines indicate the energy of a H-
bond, blue indicates an energy of -0.3–0.6 kcal/Mol, magenta: 
-0.6–1.2 kcal/Mol, red: -1.2–2.4 kcal/Mol. C atoms of NHDC 
are displayed in white and oxygen in red. Amino acid posi-
tions printed in red refer to residues emerged from the first 
round of mutational analysis and have been used as anchor 
points. Amino acid positions printed in grey were predicted 
from the model to influence receptor activation by NHDC 
and have been verified by mutational analysis.Page 5 of 12
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not be activated by NHDC, cyclamate, aspartame and ace-
sulfame K (Table 2, Additional file 1), suggesting that
these mutants are not functional. Therefore, we excluded
them from further analyses. The receptor mutant
L800F7.38 responded to NHDC in a manner similar to the
wild type receptor (Table 2, Additional file 2), suggesting
that L800 is not important for receptor activation by
NHDC. Ten receptor mutants (S620A2.57, V621I2.58,
F624L2.61, Y699L4.60, Y699F4.60, T724L5.37, R725M5.38,
S726A5.39, C801I7.39, and G804A7.42) had five to sixteen
fold increased EC50 values for NHDC (Table 2, bold script,
Additional file 2) and one mutant, G804V7.42, did not
respond to NHDC at any tested concentration (Table 2,
Additional file 1 and 2). The effects of these mutants were
specific for NHDC because they all showed similar EC50
values for aspartame (Table 2). Moreover, the functional
differences were not correlated with different expression
levels or reduced signal amplitudes (Table 2, Additional
file 3). The changes in the EC50 values suggest that these
mutations directly affect the activation of the sweet taste
receptor by NHDC, thus validating our model.
Some of the newly identified residues also influence the 
interaction of the sweet receptor with lactisole or 
cyclamate
Since our results indicate a partial overlap of the NHDC
binding site with those for lactisole and cyclamate, we
next asked, if any of the newly identified residues also
affect the sweet receptor's responses to these compounds.
To this end, we tested all mutant hTAS1R3 subunits by
coexpression with hTAS1R2 in HEK293T-G16Gust44 cells
for their sensitivity to lactisole and cyclamate (Additional
file 1). While we essentially confirmed the findings of
Jiang et al. [14,15] that amino acids in positions 6363.28,
6373.29, 6403.32, 6413.33, 721ex2, 7235.36, 7295.42, 7305.43,
7335.46, 7786.51, 7796.52, 7826.55, 790ex3, and 7987.36 of
hTAS1R3 contribute to the sensitivity of the sweet receptor
to cyclamate and/or lactisole, we found additional amino
acids in the heptahelical domain of hTAS1R3 that altered
the responses of the sweet receptor to the two com-
pounds. The mutant receptor W775A6.48 failed to respond
to lactisole (Fig. 4A), suggesting that this residue is crucial
for the sensitivity of the sweet receptor to the inhibitor.
The mutants C801I7.39 (IC50 = 0.3 ± 0.01 mM), Y699L4.60
(IC50 = 0.3 ± 0.01 mM), and Y699F4.60 (IC50 = 0.5 ± 0.01
mM) showed three- to fivefold reduced responses to lacti-
sole compared to the wild type receptor (IC50 = 0.1 ± 0.01
mM). Thus, we conclude that the amino acid positions
Y6994.60 and C8017.39 also contribute to the inhibition of
the sweet receptor by lactisole. The mutants C801I7.39 and
W775A6.48 could not be activated at any tested concentra-
tion of cyclamate indicating the importance of these resi-
dues for the sweet receptor's responsiveness to cyclamate
(Fig. 4B, Additional file 1). In addition, the mutant recep-
tor S726A5.39 displayed more than fivefold lower sensitiv-
ity to cyclamate (EC50 > 10 mM) than the wild type
receptor (EC50 = 1.9 ± 0.1 mM), suggesting that all three
residues contribute to the receptor's ability to be activated
by cyclamate.
Discussion
NHDC binds in the heptahelical domain of TAS1R3
Several independent lines of evidence clearly demonstrate
that NHDC interacts with specific amino acid residues in
the heptahelical domain of the TAS1R3 subunit. First, lac-
Table 2: Effect of mutations predicted by molecular modeling on the activation of the sweet taste receptor by neohesperidin 
dihydrochalcone (NHDC) and aspartame (ASP)
variant NHDC EC50 (mM) NHDC maximal signal 
(% of wt)
ASP EC50 (mM) ASP maximal signal 
(% of wt)
wt 0.1 ± 0.06 100 1.3 ± 0.1 100
S620A2.57 1.3 ± 0.5 55 ± 80 1.2 ± 0.3 64 ± 4
V621L2.58 n.f. --- n.f. ---
V621I2.58 >1 60 ± 14 1.9 ± 0.4 61 ± 1
F624L2.61 >1 35 ± 70 1.4 ± 0.2 21 ± 4
Y699L4.60 0.7 ± 0.1 83 ± 40 1.6 ± 0.4 78 ± 9
Y699F4.60 0.6 ± 0.4 72 ± 17 1.2 ± 0.3 56 ± 2
T724L5.37 0.5 ± 0.3 58 ± 60 1.5 ± 0.2 69 ± 2
R725M5.38 1.3 ± 0.4 64 ± 14 1.5 ± 0.7 56 ± 1
S726A5.39 0.9 ± 0.3 60 ± 50 0.9 ± 0.3 50 ± 2
L800F7.38 0.2 ± 0.1 91 ± 70 1.2 ± 0.3 90 ± 1
C801I7.39 1.6 ± 0.7 70 ± 13 1.2 ± 0.5 50 ± 9
C801L7.39 n.f. --- n.f. ---
G804A7.42 1.3 ± 0.5 53 ± 10 1.6 ± 0.2 44 ± 1
G804V7.42 n.r. --- 1.3 ± 0.3 21 ± 2
Receptor variants that affect the NHDC response are shown in bold. Values are given as average over at least three independent experiments ± 
SD. n.f. no response to any tested sweetener, n.r. no response to neohesperidin dihydrochalcone up to highest tested concentration (6 mM), but 
responses to other sweeteners. (>), EC50 not calculable because saturation is not reached (Additional file 2).Page 6 of 12
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TAS1R3 [13,15], inhibited the activation of hTAS1R2/
hTAS1R3 by NHDC competitively, while sweeteners that
interact with other parts of the receptor were allosterically
inhibited (Fig. 2). Second, the functional analysis of rat/
human TAS1R2/TAS1R3 chimeric receptors showed that
NHDC activated all chimeric receptors that contain the
heptahelical domain of human TAS1R3. In contrast, all
chimeras that contained the heptahelical domain of rat
Tas1r3 could not be activated by NHDC (Fig. 1). Third,
seventeen amino acid exchanges in the heptahelical
domain of hTAS1R3 specifically reduced the NHDC
responses but did not influence the responses to aspar-
tame (Table 1 + 2), which interacts with the extracellular
N-terminal domain of TAS1R2 [13]. Moreover, the find-
ing that NHDC activates the human sweet receptor but
not the rat sweet taste taste receptor delivers a molecular
basis for the well-known lack of NHDC preference in
rodents [25,26]. In addition, our results confirm previous
findings that functional differences between rat and
human sweet receptor [4] are caused by sequence varia-
tions in the heptahelical domain of TAS1R3 [13,14,16].
Elucidation of the NHDC binding site
To further understand the interaction between NHDC and
the heptahelical domain of hTAS1R3 we established a
simple 3D receptor pharmacophore model of the NHDC
binding site. Notably, in the model each amino acid resi-
due in the heptahelical domain of the TAS1R3 receptor is
identified by its position. Moreover, the numbering sys-
tem proposed by Ballesteros and Weinstein [27] is shown
as superscripts to facilitate the comparison with results of
other GPCRs. The model considers results obtained from
our functional studies, available data about the suggested
binding modes of cyclamate and lactisole [14,15], infor-
mation about conserved amino acids in GPCRs [27], and
sensory studies of NHDC derivatives [23,24]. These sen-
sory studies have shown that the hydroxyl group in C3 of
the B ring is crucial for the sweet taste of dihydrochalcones
[23,28]. In line with these findings, our receptor model
proposes that this hydroxyl group can form hydrogen
bonds with either of the two serine residues in positions
6403.32 of TM3 and 6202.57 of TM2. The possible interac-
tion of the C3 hydroxyl group with both serines can
explain why mutations at either position strongly reduced
but not completely abolished the responses of the recep-
tor to NHDC.
The model also predicts that H6413.33, Q6373.29, and
C8017.39 can form hydrogen bonds with hydroxyl groups
in the A ring as suggested by the decreased EC50 values for
NHDC of the corresponding mutants. In addition, our
model predicts that hydroxyl groups of the sugar moieties
interact with Y6994.60, R7255.38, and S7265.39 in TM4 and
TM5. Indeed, mutations in these positions impaired the
interaction of NHDC with the receptor. Notably, the agly-
con hesperitin dihydrochalcone that lacks the sugar rings
also tastes sweet [29,30]. Therefore, it might be conceiva-
ble that amino acids at these three positions are less
important for the activation of the sweet taste receptor by
NHDC, but rather enhance its affinity. Furthermore, the
methoxy group at position C4 of the B ring is in close
proximity to V6212.58 and F6242.61 and is therefore likely
Identification of additional determinants in TAS1R3 critical for responsiveness to cyc amate and lact soleFigure 4
Identification of additional determinants in TAS1R3 
critical for responsiveness to cyclamate and lactisole. 
(A) Concentration-dependent inhibition of calcium responses 
to 10 mM aspartame by lactisole in HEK293T-G16Gust44 
cells cotransfected with DNA for wild type hTAS1R2/
hTAS1R3 (filled circle, solid line), C801I7.39 (open diamond, 
short dashed line), Y699L5.60 (open circle, dash-dot-dotted 
line), Y699F5.60 (filled triangle up, medium dashed line), or 
W775A6.48 (filled hexagon, dash-dotted line) and hTAS1R2 
DNA. (B) Concentration-dependent responses of HEK293T-
G16Gust44 cells to cyclamate cotransfected with DNA for 
hTAS1R3 (filled circle, solid line), S726A5.39 (open triangle up, 
medium dashed line), C801I7.39 (open diamond, short dashed 
line), or W775A6.48 (filled hexagon, dash-dotted line) and 
hTAS1R2.Page 7 of 12
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side chains of these amino acids as concluded from the
shift in EC50 values for NHDC at the corresponding
mutant receptors.
The binding sites for NHDC, cyclamate and lactisole share 
amino acid residues
The sweet inhibitor lactisole, which interacts with specific
residues in the heptahelical domain of TAS1R3
[13,15,16], inhibited the activation of the sweet receptor
by NHDC and cyclamate competitively (Fig. 2). These
results suggest that the binding sites of lactisole, cycla-
mate, and NHDC overlap. Interestingly, the observed
competitive effects between NHDC and lactisole (Fig. 2)
may also explain why lactisole in contrast to many other
sweeteners did not inhibit the sweet taste of NHDC in
humans [31]. A previous report of Jiang et al. proposed
that cyclamate and lactisole interact with a common set of
amino acid residues[14,15]. Our findings confirm this
observation by showing that seven mutations (Q6373.29,
H6413.33, W7756.48, F7786.51, L7826.55, R790Qex3, and
C8017.39) influence both, the lactisole mediated inhibi-
tion and the cyclamate induced activation of the sweet
receptor (Fig. 5, Table 1 + 2). While cyclamate and lacti-
sole only use parts of the TAS1R3 pharmacophore, our
model predicts that NHDC uses most of it due to its larger
size (Fig. 3). In line with these predictions, eight of the
seventeen amino acids that alter receptor activation by
NHDC (Q6373.29, S6403.32, H6413.33, Y6994.60, W7756.48,
F7786.51, L7826.55, and C8017.39), also influence lactisole-
mediated inhibition of the receptor. Similarly, nine of the
seventeen residues (Q6373.29, H6413.33, H721ex2,
S7265.39, F7305.43, W7756.48, F7786.51, L7826.55, and
C8017.39) mediate activation by cyclamate, while six
(Q6373.29, H6413.33, W7756.48, F7786.51, L7826.55, and
C8017.39) influence receptor inhibition by lactisole as well
as receptor activation by cyclamate (Fig. 5, Table 1 + 2).
Our mutational analysis identified four additional amino
acid residues that have not previously been recognized
(Y6994.60, S7265.39, W7756.48, and C8017.39) as interaction
partners for lactisole and cyclamate [14,15]. These resi-
dues nicely refine the model proposed by Jiang et al. by
enabling additional interactions between the two com-
pounds and TAS1R3. This finding supports the validity of
our model and suggests that it is compatible with that of
Jiang et al.
Transmembrane domains six and seven are generally
involved in GPCR activation [32-34]. The following
observations suggest that the four residues W775A6.48,
F778A6.51, L782A6.55, and C801I7.39 of TM6 and TM7
could participate in conformational changes of the sweet
taste receptor from the ground to an active state and vice
versa. Firstly, F7786.51 and W7756.48 are highly conserved
across class A and class C GPCRs [14,15,35]. Secondly,
our study showed that mutations at these positions alter
the receptor's sensitivities to the agonists NHDC and
cyclamate as well as to the inhibitor lactisole. Thirdly,
Jiang et al. also found that mutations in position
L782A6.55 abolished activation of the sweet taste receptor
by cyclamate and enhanced the receptor's responsiveness
to the inhibitor lactisole [15].
The amino acid residue C8017.39 in TM7 also affects the
sensitivity of the sweet taste receptor to cyclamate, NHDC
and lactisole. While it is in the proximity of the NHDC
Alignment of the heptahelical domain of hCaSR, hmGlu2, rmGlu1, rmGlu5, and hTAS1R3Figure 5
Alignment of the heptahelical domain of hCaSR, 
hmGlu2, rmGlu1, rmGlu5, and hTAS1R3. Transmem-
brane segments (TM) are shown in bold. Intra- and extracel-
lular loops are marked by ICL and ECL, respectively. Amino 
acids that influence allosteric modulator activity in hCaSR, 
hmGlu2, rmGlu1 and 5 are marked in grey. Positions that 
alter the response of the sweet receptor to lactisole, cycla-
mate, or NHDC are shown in red. Asterisks indicate resi-
dues involved in receptor activation by NHDC (orange) or 
cyclamate (blue). Green asteriks denote residues mediating 
sensitivity of the receptor to lactisole.Page 8 of 12
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lactisole (Fig. 3A, B, C). This argues against a direct inter-
action of lactisole with C8017.39. It is therefore conceiva-
ble that in addition to W7756.48, F7786.51, and L7826.55 in
TM6, C8017.39 in TM7 may also play a general role in the
activation process of the sweet taste receptor. This
assumption is further supported by the observation that
amino acids in TM7 of the calcium sensing receptor such
as V8367.31, Q8377.32 and A8437.38 play a key role in the
activation of this receptor [32].
Notably, aspartame, which likely interacts with the N-ter-
minal domain of hTAS1R2 [12,13] could activate the
mutants W7756.48, F7786.51, L7826.55 and C801I7.39 in a
manner, similar to the wild type receptor (Tab. 1 and 2).
Therefore, it might be possible that tastants that bind to
different receptor sites elicit different types of active con-
firmations as has been observed before for the activation
of the β2-adrenergic receptor by salbutamol and catechol
[36].
The NHDC binding site overlaps with the binding sites of 
allosteric modulators in other class C GPCRs
Sequence comparisons revealed that nine of the amino
acid positions in hTAS1R3 that influence the sensitivity of
the sweet receptor to NHDC, cyclamate or lactisole corre-
spond to residues that are responsible for binding allos-
teric modulators in the calcium sensing receptor and
metabotropic glutamate receptors (Fig. 5) [32-34,37-43].
This suggests a general role for these positions in alloster-
ism in this class of receptors and shows that positions of
allosteric binding sites are partly conserved amongst class
C GPCRs. Thus, critical determinants found in non-taste
receptors are good candidates to uncover additional bind-
ing sites for sweet and umami tasting substances or mod-
ulators.
Conclusion
Our mutational analysis combined with functional stud-
ies and molecular modeling identified the binding pocket
of NHDC in the heptahelical domain of human TAS1R3.
We found that the binding pocket of NHDC overlaps with
those of the sweetener cyclamate and the sweet taste
inhibitor lactisole. Seven of the amino acid positions cru-
cial for activation of hTAS1R2/hTAS1R3 by neohesperidin
dihydrochalcone are involved in the binding of allosteric
modulators of other class C GPCRs. This suggests a gen-
eral role of these amino acid positions in allosterism and
points to a common architecture of the heptahelical
domains of class C GPCRs.
Methods
Ballesteros and Weinstein nomenclature
The position of each amino acid residue in the heptaheli-
cal domain of TAS1R3 is identified both by its position
and by the generic numbering system proposed by Balles-
teros and Weinstein [27] shown as superscripts. In the Bal-
lesteros-Weinstein nomenclature the most conserved
residue in each helix is given the number 50. This is
N1.50, D2.50, R3.50, W4.50, P5.50, P6.50 and P7.50 in
transmembrane helix 1–7 of the rhodopsin receptor. The
corresponding amino acids in the TAS1R3 are given the
same numbers (Additional file 4).
Construction of TAS1R3 mutants
Human TAS1R3 receptor mutants were generated by site
directed mutagenesis according to the QuickChange pro-
tocol (Stratagene, La Jolla, CA). The forward and reverse
primers contained the desired mutations and annealed to
the same sequence on opposite strands of the plasmids.
The following TAS1R3 receptor mutants were generated:
S620A2.57, V621L2.58, V621I2.58, F624L2.61, Q636A3.28,
Q637E3.29, S640A3.32, H641A3.33, Y699L4.60, Y699F4.60,
H721Aex2, R723A5.36, T724L5.37, R725M5.38, S726A5.39,
S729A5.42, F730L5.43, A733V5.46, H734A5.47, W775A6.48,
F778A6.51, V779A6.52, L782A6.55, R790Qex3, L798I7.36,
L800F7.38, C801L7.39, C801I7.39, G804V7.42, and
G804A7.42.
The position of each amino acid residue in the seven hep-
tahelical domain of the TAS1R3 receptor is identified both
by its position and by the generic numbering system pro-
posed by Ballesteros and Weinstein [27] shown as super-
scripts.
Functional expression
The cDNAs for TAS1Rs tagged at the C-terminus with the
herpes simplex virus glycoprotein D (HSV) were tran-
siently transfected into HEK293T cells stably expressing
the chimeric G-protein subunit G16Gust44 [44] using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer's protocol. 3–4 hours after transfec-
tion, DMEM was replaced by low-glucose DMEM supple-
mented with GlutaMAX and 10% dialyzed FBS
(Invitrogen, Carlsbad, CA). 24 h post transfection, cells
were loaded for 1 h with the calcium sensitive dye Fluo4-
AM (2 µg/ml in DMEM, Molecular Probes, Carlsbad, CA).
Cells were washed 3x in solution C1 (130 mM NaCl, 5
mM KCl, 10 mM Hepes, 2 mM CaCl2, and 5 mM Glucose,
pH 7,4). We monitored calcium mobilization following
receptor stimulation with sweet tastants by an automated
fluorometric imaging plate reader (FLIPR, Molecular
Devices, Sunnyvale, CA). Compounds used as stimuli
(Sigma-Aldrich, St. Louis, MO; Merck, Whitehouse Sta-
tion, NJ) were dissolved in C1 solution. All data were col-
lected from at least three independent experiments carried
out in duplicate. The obtained calcium signals were cor-
rected for the response of mock transfected cells and nor-
malized to the fluorescence of cells prior to the
application of the stimulus using ∆F/F = (F-F0)/F0. Con-Page 9 of 12
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calculated in SigmaPlot by nonlinear regression using the
function f = ((a-d)/(1+(x/EC50)nH)+d) and f = (a-b)/
[1+(x/IC50)nH]+b, respectively.
Immuncytochemistry
HEK293T-G16Gust44 cells were seeded on poly-D-lysine
coated coverslips (10 µg/ml) and transfected with the
respective cDNAs. 24 h post transfection cells were
washed with PBS and fixed and permeabilized for 5 min
in acetone/methanol (1:1). Incubating the cells in 5%
goat serum for 30 min reduced non-specific binding. To
detect the receptors, antiserum against the HSV-epitope
(mouse anti-HSV (Novagen, Madison, WI), 1:10000 in
3% goat serum) was added to the cells for 1 h at room
temperature (RT). After washing the cells three times with
PBS we added Alexa488-conjugated goat antiserum
against mouse IgG (Molecular Probes, Carlsbad, CA),
1:1000 in 3% goat serum) for 1 h at RT. The cells were
embedded in Fluorescent Mounting Medium (Dako,
Glostrup, Denmark) and analyzed using a fluorescence
microscope (Zeiss Axioplan, Jena, Germany) and a cam-
era (RT Slide, Visitron Systems, Munich, Germany).
TAS1R3 modeling
All modeling calculations were made on a Silicon Graph-
ics Octane with a single R12000 processor using our in-
house modeling package Moloc [45]. The alignment of
the seven transmembrane helices of TAS1R3 receptor
(SWISS-PROT: TS1R3_HUMAN, Q7RTX0) with the trans-
membrane helices of bovine rhodopsin (pdb ref code
1f88) and the 3D receptor-based pharmacophore mode-
ling was described previously [22]. Briefly, the method
relies on a robust alignment algorithm based on conserva-
tion indices, focusing on pharmacophore-like relation-
ships between amino acids. Analysis of conservation
patterns across the GPCR family and alignment to the rho-
dopsin x-ray structure (pdb ref code 1f88, Additional file
4) allows the extraction of the amino acids lining the TM
binding pocket in a so-called ligand binding pocket vec-
tor. In a second step, LPVs are translated to simple 3D
receptor pharmacophore models, where a single spherical
pharmacophore feature represents each amino acid and
all atomic detail is omitted. The pharmacophores are
colored according to the pharmacophoric properties of
the amino acids. Hydrophobic amino acids (aromatic/
aliphatic; F, P, M, A, L, I, G, V, W) are represented by cyan
pharmacophores, amino acids with H-donor/acceptor
functionalities (Y, T, S, H, C, N, Q) by magenta pharma-
cophores, and amino acids with H-bond donor function-
alities and positive charge (K, R) by blue ones. The
pharmacophores with H-bond donor or acceptor proper-
ties have in addition a cone, which gives the most likely
direction of the H-bond. The new reported receptor-based
pharmacophore modeling methodology allows a visual
analysis of the general ligand binding properties of any
GPCR without the need to concentrate on atomic details
of side chain orientations [22]. NHDC is manually
docked into the pharmacophores in the TM pocket. Only
pharmacophores are shown which were identified as
important for the action of NHDC by site-directed muta-
genesis.
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